NCT02238782 - A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy Volunteers Bioavailability Study

Interventions

DRUG

selumetinib 75mg single dose

3 capsules of 25 mg given as a single dose

OTHER

[14C] selumetinib IV solution

single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose

Trial Locations (1)

Unknown

Research Site, Nottingham